Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyorin Gains Rights to Merck’s OAB Med in Asia
April 12, 2017
- Japan Authorized Generic Market Projected to Reach 81.7 Billion Yen in 2020: Fuji Keizai
April 11, 2017
- Takeda Sells Actos, Other Long-Listed Brands to Teva JV
April 11, 2017
- Ethical Drug Sales Sag 11.3% in February: Crecon
April 11, 2017
- Sumitomo Dainippon Gives Bukwang Korean Rights for Lurasidone
April 11, 2017
- Santen Makes Strategic Investment in US Cell Therapy Technology Firm
April 10, 2017
- Mogamulizumab Hits Primary Endpoint in PIII for CTCL: Kyowa Kirin
April 10, 2017
- Kyowa Kirin’s KRN23 Delivers Positive PII Data for Pediatric X-Linked Hypophosphatemia
April 10, 2017
- Takeda-PRA Joint Venture in Japan to Be Formed on June 1
April 10, 2017
- Trerief Delivers Positive Results in Lewy Body Dementia: Sumitomo Dainippon
April 7, 2017
- Boehringer Japan to Spur Joint Drug Discovery Research, Eyes 1st Clinical Trial in 2020
April 7, 2017
- Takeda Earns Global Rights to Finch’s Microbiome IBD Therapy
April 7, 2017
- Takeda’s Massive Dengue Trial Enrollment Completed
April 7, 2017
- Heptares Gains Preclinical Milestone in AZ Immuno-Oncology Deal
April 6, 2017
- Eisai Gets Japan, Asian Rights to Safinamide from Meiji
April 6, 2017
- Actelion’s Flolan Generic Outstrips Originator in Pediatric Use with Rare Dosage Nod; Japan Chief Says Company Fulfilling Maker’s Responsibility
April 6, 2017
- Mochida Aims for Sales of 107 Billion Yen in FY2017 under New 3 Year Biz Plan
April 5, 2017
- Daiichi Sankyo Sells US Packaging Plant
April 5, 2017
- Bayer Yakuhin Running Pilot AI Program for Sales Rep Support
April 5, 2017
- MSD Japan President Pins High Hopes on Keytruda Growth in 2017 after 7.8% Sales Dip
April 5, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…